Show simple item record

dc.contributor.authorShimada, Yoichiro
dc.contributor.authorHeard, Henry
dc.date.accessioned2021-04-06T20:16:56Z
dc.date.available2021-04-06T20:16:56Z
dc.date.issued2021
dc.identifier.urihttp://hdl.handle.net/10898/12538
dc.description.abstractPlatelet-rich plasma (PRP), also referred to as autologous platelet gel, has been increasingly used for musculoskeletal injuries, including Achilles tendonitis, shoulder impingement, rotator cuff tear, lateral epicondylitis, patellar tendinopathy, and plantar fasciitis. Chronic plantar fasciitis is defined as degenerative irritation of the plantar fascia that has failed to respond to conservative therapy, and it presents with non-inflammatory, fibroblastic hypertrophy and dysfunctional vasculature. With the chronic degenerative changes of the tissue along with zones of avascularity, chronic plantar fasciitis is difficult to treat, and the recurrence is common even after prolonged rest. Current treatments for chronic plantar fasciitis include corticosteroid injection, extracorporeal shock wave therapy, and surgery. Corticosteroid injections are common treatments for chronic plantar fasciitis; however, there are potential disabling complications associated with corticosteroid injections. PRP has been proposed as an effective, safer alternative treatment option for chronic plantar fasciitis. Due to the hypovascularity and hypocellularity nature of the injury, directly introducing growth factors and cytokines found in PRP to the fascia is believed to promote tissue heal. The purpose of this review is to examine current literature on PRP treatment for chronic plantar fasciitis.
dc.subjectCollege of Health Professions
dc.subjectARC21--Night 3
dc.titlePlatelet-Rich Plasma for Chronic Plantar Fasciitis
dc.typePresentation
refterms.dateFOA2021-04-06T20:16:56Z


Files in this item

Thumbnail
Name:
ARC21_COHP_020.pdf
Size:
298.7Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record